Cargando…
European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2
BACKGROUND: Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T‐cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well as refractory forms. After the publicat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821314/ https://www.ncbi.nlm.nih.gov/pubmed/32964529 http://dx.doi.org/10.1111/jdv.16889 |
_version_ | 1783639396881268736 |
---|---|
author | Knobler, R. Arenberger, P. Arun, A. Assaf, C. Bagot, M. Berlin, G. Bohbot, A. Calzavara‐Pinton, P. Child, F. Cho, A. French, L.E. Gennery, A.R. Gniadecki, R. Gollnick, H.P.M. Guenova, E. Jaksch, P. Jantschitsch, C. Klemke, C. Ludvigsson, J. Papadavid, E. Scarisbrick, J. Schwarz, T. Stadler, R. Wolf, P. Zic, J. Zouboulis, C. Zuckermann, A. Greinix, H. |
author_facet | Knobler, R. Arenberger, P. Arun, A. Assaf, C. Bagot, M. Berlin, G. Bohbot, A. Calzavara‐Pinton, P. Child, F. Cho, A. French, L.E. Gennery, A.R. Gniadecki, R. Gollnick, H.P.M. Guenova, E. Jaksch, P. Jantschitsch, C. Klemke, C. Ludvigsson, J. Papadavid, E. Scarisbrick, J. Schwarz, T. Stadler, R. Wolf, P. Zic, J. Zouboulis, C. Zuckermann, A. Greinix, H. |
author_sort | Knobler, R. |
collection | PubMed |
description | BACKGROUND: Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T‐cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well as refractory forms. After the publication of the first guidelines for this technology in the JEADV in 2014, this technology has maintained additional promise in the treatment of other severe and refractory conditions in a multidisciplinary setting. It has confirmed recognition in well‐known documented conditions such as graft‐vs.‐host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection including lung, heart and liver and to a lesser extent inflammatory bowel disease. MATERIALS AND METHODS: In order to further provide recognized expert practical guidelines for the use of this technology for all indications, the European Dermatology Forum (EDF) again proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. This was done using the recognized and approved guidelines of EDF for this task. All authors had the opportunity to review each contribution as it was added. RESULTS AND CONCLUSION: These updated 2020 guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion. The guidelines were divided into two parts: PART I covers Cutaneous T‐cell lymphoma, chronic graft‐vs.‐host disease and acute graft‐vs.‐host disease, while PART II will cover scleroderma, solid organ transplantation, Crohn’s disease, use of ECP in paediatric patients, atopic dermatitis, type 1 diabetes, pemphigus, epidermolysis bullosa acquisita and erosive oral lichen planus. |
format | Online Article Text |
id | pubmed-7821314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78213142021-01-29 European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2 Knobler, R. Arenberger, P. Arun, A. Assaf, C. Bagot, M. Berlin, G. Bohbot, A. Calzavara‐Pinton, P. Child, F. Cho, A. French, L.E. Gennery, A.R. Gniadecki, R. Gollnick, H.P.M. Guenova, E. Jaksch, P. Jantschitsch, C. Klemke, C. Ludvigsson, J. Papadavid, E. Scarisbrick, J. Schwarz, T. Stadler, R. Wolf, P. Zic, J. Zouboulis, C. Zuckermann, A. Greinix, H. J Eur Acad Dermatol Venereol Guidelines and Position Statements BACKGROUND: Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T‐cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well as refractory forms. After the publication of the first guidelines for this technology in the JEADV in 2014, this technology has maintained additional promise in the treatment of other severe and refractory conditions in a multidisciplinary setting. It has confirmed recognition in well‐known documented conditions such as graft‐vs.‐host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection including lung, heart and liver and to a lesser extent inflammatory bowel disease. MATERIALS AND METHODS: In order to further provide recognized expert practical guidelines for the use of this technology for all indications, the European Dermatology Forum (EDF) again proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. This was done using the recognized and approved guidelines of EDF for this task. All authors had the opportunity to review each contribution as it was added. RESULTS AND CONCLUSION: These updated 2020 guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion. The guidelines were divided into two parts: PART I covers Cutaneous T‐cell lymphoma, chronic graft‐vs.‐host disease and acute graft‐vs.‐host disease, while PART II will cover scleroderma, solid organ transplantation, Crohn’s disease, use of ECP in paediatric patients, atopic dermatitis, type 1 diabetes, pemphigus, epidermolysis bullosa acquisita and erosive oral lichen planus. John Wiley and Sons Inc. 2020-09-22 2021-01 /pmc/articles/PMC7821314/ /pubmed/32964529 http://dx.doi.org/10.1111/jdv.16889 Text en © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Guidelines and Position Statements Knobler, R. Arenberger, P. Arun, A. Assaf, C. Bagot, M. Berlin, G. Bohbot, A. Calzavara‐Pinton, P. Child, F. Cho, A. French, L.E. Gennery, A.R. Gniadecki, R. Gollnick, H.P.M. Guenova, E. Jaksch, P. Jantschitsch, C. Klemke, C. Ludvigsson, J. Papadavid, E. Scarisbrick, J. Schwarz, T. Stadler, R. Wolf, P. Zic, J. Zouboulis, C. Zuckermann, A. Greinix, H. European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2 |
title | European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2 |
title_full | European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2 |
title_fullStr | European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2 |
title_full_unstemmed | European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2 |
title_short | European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2 |
title_sort | european dermatology forum: updated guidelines on the use of extracorporeal photopheresis 2020 – part 2 |
topic | Guidelines and Position Statements |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821314/ https://www.ncbi.nlm.nih.gov/pubmed/32964529 http://dx.doi.org/10.1111/jdv.16889 |
work_keys_str_mv | AT knoblerr europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT arenbergerp europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT aruna europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT assafc europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT bagotm europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT berling europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT bohbota europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT calzavarapintonp europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT childf europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT choa europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT frenchle europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT genneryar europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT gniadeckir europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT gollnickhpm europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT guenovae europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT jakschp europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT jantschitschc europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT klemkec europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT ludvigssonj europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT papadavide europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT scarisbrickj europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT schwarzt europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT stadlerr europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT wolfp europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT zicj europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT zouboulisc europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT zuckermanna europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 AT greinixh europeandermatologyforumupdatedguidelinesontheuseofextracorporealphotopheresis2020part2 |